AMENDED AND RESTATED COMMON STOCK PURCHASE WARRANT Hancock Jaffe Laboratories, Inc.Hancock Jaffe Laboratories, Inc. • April 16th, 2018 • Surgical & medical instruments & apparatus • New York
THIS AMENDED AND RESTATED COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received [*] or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth and in the Securities Purchase Agreement, dated as of January 5, 2018, by and among Hancock Jaffe Laboratories, Inc., a Delaware corporation (the “Company”) and the Holders signatory thereto, as amended, modified or supplemented from time to time in accordance with its terms (as it may be amended, amended and restated or otherwise modified from time to time, the “Purchase Agreement”), at any time on or after the Original Issue Date and on or prior to the close of business on the fifth (5th) anniversary of the Original Issue Date (the “Termination Date”) but not thereafter, to subscribe for and purchase from the Company, subject to adjustment as set forth in Section 2.2(a)(iii) of the Purchase Agreement, up to a number of shares of the Co
HANCOCK JAFFE LABORATORIES, INC. EMPLOYMENT AGREEMENTEmployment Agreement • April 16th, 2018 • Hancock Jaffe Laboratories, Inc. • Surgical & medical instruments & apparatus • California
This Employment Agreement (“Agreement”), dated as of March 30, 2018 (the “Effective Date”), is made by and between Hancock Jaffe Laboratories, Inc. (“Hancock Jaffe”) and Robert A. Berman (“Executive,” and together with Hancock Jaffe, the “Parties”).
AMENDED AND RESTATED CONVERTIBLE NOTEHancock Jaffe Laboratories, Inc. • April 16th, 2018 • Surgical & medical instruments & apparatus • New York
THIS AMENDED AND RESTATED CONVERTIBLE NOTE is one of a series of duly authorized and validly issued Convertible Notes of Hancock Jaffe Laboratories, Inc., a Delaware corporation (the “Company”), having its principal place of business at 70 Doppler Irvine, California, 92618 (this Note, the “Note” and, collectively with the other Notes of such series, the “Notes”).
SECOND AMENDMENT TO SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • April 16th, 2018 • Hancock Jaffe Laboratories, Inc. • Surgical & medical instruments & apparatus • Delaware
This SECOND AMENDMENT TO SECURITIES PURCHASE AGREEMENT (this “Amendment”), dated as of February __, 2018, is by and among Hancock Jaffe Laboratories, Inc., a Delaware corporation (the “Company”), and the undersigned signatories hereto (collectively, the “Lenders”), and further amends that certain Securities Purchase Agreement, dated as of June 15, 2017, as amended on December 29, 2017, by and among the Company and the signatories thereto (the “Purchasers” and altogether, the “Purchase Agreement”), the Amended and Restated Convertible Notes issued pursuant to the Purchase Agreement (the “2017 Notes”), and the Amended and Restated Common Stock Purchase Warrants issued pursuant to the Purchase Agreement (the “2017 Warrants” and, together with the Purchase Agreement and the 2017 Notes, the “Transaction Documents”). Capitalized terms used but not defined herein shall have the meaning ascribed to such terms in the Transaction Documents.
FIRST AMENDMENT TO EMPLOYMENT AGREEMENTEmployment Agreement • April 16th, 2018 • Hancock Jaffe Laboratories, Inc. • Surgical & medical instruments & apparatus • California
This First Amendment to Employment Agreement (this “Amendment”), dated as of April 2, 2018 (the “Effective Date”), is made by and between Hancock Jaffe Laboratories, Inc., a Delaware corporation (“Hancock Jaffe”) and Benedict Broennimann, M.D.(“Executive,” and together with Hancock Jaffe, the “Parties”), and amends that certain Employment Agreement, dated as of August 30, 2016, by and between Hancock Jaffe and Executive (the “Employment Agreement”).
AMENDMENT TO SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • April 16th, 2018 • Hancock Jaffe Laboratories, Inc. • Surgical & medical instruments & apparatus • Delaware
This AMENDMENT TO SECURITIES PURCHASE AGREEMENT (this “Amendment”), dated as of February __, 2018, is by and among Hancock Jaffe Laboratories, Inc., a Delaware corporation (the “Company”), and the undersigned signatories hereto (collectively, the “Lenders”), and amends that certain Securities Purchase Agreement, dated as of January 5, 2018, by and among the Company and the signatories thereto (the “Purchasers” and altogether, the “Purchase Agreement”), the Convertible Notes issued pursuant to the Purchase Agreement (the “2018 Notes”), and the Common Stock Purchase Warrants issued pursuant to the Purchase Agreement (the “2018 Warrants” and, together with the Purchase Agreement and the 2018 Notes, the “Transaction Documents”). Capitalized terms used but not defined herein shall have the meaning ascribed to such terms in the Transaction Documents.
AMENDMENT TO WARRANT TO PURCHASE SHARESWarrant to Purchase Shares • April 16th, 2018 • Hancock Jaffe Laboratories, Inc. • Surgical & medical instruments & apparatus
This Amendment to Warrant to Purchase Shares (this “Amendment”), dated as of April 6, 2018, is by and between Hancock Jaffe Laboratories, Inc., a Delaware corporation (the “Company”), and [___________] (the “Holder”), and amends that certain Warrant to Purchase Shares, issued as of [__________], by the Company to the Holder (the “Warrant”). Capitalized terms used but not defined herein shall have the meaning ascribed to such terms in the Warrant.
TO LOAN AGREEMENTLoan Agreement • April 16th, 2018 • Hancock Jaffe Laboratories, Inc. • Surgical & medical instruments & apparatus
This Amendment to Loan Agreement DRICBDH0615 (the “Amendment”) is made and entered into as of January 11, 2018, by and between Biodyne Holding SA, a Swiss corporation (the “Lender”) and Hancock Jaffe Laboratories, Inc., a Delaware corporation, (the “Borrower”).
TO LOAN AGREEMENTLoan Agreement • April 16th, 2018 • Hancock Jaffe Laboratories, Inc. • Surgical & medical instruments & apparatus
This Amendment to Loan Agreement DRICBDH0615 (the “Amendment”) is made and entered into as of March 30, 2018, by and between Biodyne Holding SA, a Swiss corporation (the “Lender”) and Hancock Jaffe Laboratories, Inc., a Delaware corporation, (the “Borrower”).
